NASDAQ$IMNM
Immunome Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
Immunome reported its Q4 and full year 2020 financial results, highlighting a transformational period marked by a successful NASDAQ IPO that raised $44.9 million in gross proceeds. The company is advancing its IMM-ONC-01 program into IND-enabling studies and expects to provide development program updates in the second quarter of 2021.
- Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing (IMM-BCP-01).
- Advanced proprietary antibody against IL-38 into IND-enabling studies (IMM-ONC-01).
- Raised $44.9 million in gross proceeds in NASDAQ IPO.
- Program updates expected in 2Q 2021.
Headline financials
Revenue & EPS history
Immunome · Revenue · Quarterly
$0
Forward guidance
Immunome anticipates providing development program updates in Q2 2021 and intends to file INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021.
Tailwinds
- Development program updates expected in the second quarter of 2021.
- Filing INDs for both IMM-BCP-01 and IMM-ONC-01 in 2021.
- Prospects for both of current development programs.
- Confidence in discovery engine to move one to two new candidates into IND-enabling studies per year.
- Isolation of antibodies capable of neutralizing SARs-CoV-2 variants in pseudovirus testing as part of IMM-BCP-01 program.
Headwinds
- Impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones.
- Ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones.
- Timing and effectiveness of any antibody therapeutics which may be developed by Immunome.
- Ability to fund operations.
- Risks and uncertainties associated with Immunome’s business
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+0.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+24.1%
Q4 2021
Best reaction
-10.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.3% | -9.1% | -20.0% | |
| Q4 2025 | +4.7% | -1.0% | +1.4% | |
| Q3 2025 | -5.0% | +2.5% | +12.3% | |
| Q1 2025 | +1.1% | -1.0% | +15.0% | |
| Q4 2024 | -4.0% | -18.9% | -7.7% | |
| Q3 2024 | -10.8% | -24.5% | +0.7% | |
| Q2 2024 | +4.7% | +4.7% | +11.9% | |
| Q1 2024 | -1.3% | -6.2% | -3.2% | |
| Q4 2023 | -2.3% | -16.2% | -46.2% | |
| Q3 2023 | -8.1% | -8.9% | -12.2% | |
| Q2 2023 | -1.9% | -0.8% | +3.9% | |
| Q1 2023 | +2.3% | +11.9% | -6.2% | |
| Q4 2022 | +20.8% | +18.9% | +2.3% | |
| Q3 2022 | +0.0% | -27.6% | -8.5% | |
| Q2 2022 | +19.3% | +13.6% | +24.7% | |
| Q1 2022 | -2.6% | +19.6% | +46.5% | |
| Q4 2021 | +24.1% | +20.1% | -26.3% | |
| Q3 2021 | -1.0% | -5.1% | -9.3% | |
| Q2 2021 | -3.2% | -11.9% | +51.2% | |
| Q1 2021 | -10.7% | -3.0% | -2.9% | |
| Q4 2020 | -1.0% | -4.3% | -8.3% | |
| Q3 2020 | -5.5% | -6.4% | -6.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro